Where Will Aquestive Therapeutics Inc (AQST) Stock Go Next After It Is Down 6.02% in a Week?

Overall market sentiment has been neutral on Aquestive Therapeutics Inc (AQST) stock lately. AQST receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.

Aquestive Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on AQST!

See Full AQST Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With AQST Stock Today?

Aquestive Therapeutics Inc (AQST) stock is down -2.87% while the S&P 500 has risen 0.1% as of 10:31 AM on Wednesday, Apr 20. AQST is down -$0.06 from the previous closing price of $2.09 on volume of 19,333 shares. Over the past year the S&P 500 has risen 7.29% while AQST is down -50.97%. AQST lost -$1.85 per share in the over the last 12 months. To screen for more stocks like Aquestive Therapeutics Inc click here.

More About Aquestive Therapeutics Inc

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States. Click Here to get the full Stock Report for Aquestive Therapeutics Inc stock.